Current Clinical Trials

Hypogonadism-Leflutrozole

The goal of this clinical trial is to evaluate three doses of the drug leflutrozole on improvement of semen quality in men with hypogonadotropic hypogonadism, a condition that affects hormone levels and fertility. It will also study the safety of leflutrozole.
 

Participants must be adult men aged 18-49 years who are not currently taking testosterone replacement therapy.

​

​

​

 

Hypogonadism-ABPM

A Phase 4, multi-center, open-label, single-arm 24-hour Ambulatory Blood Pressure Monitoring (ABPM) study of Testosterone Cypionate Injection in Hypogonadal Men to assess change in 24-hour ambulatory blood pressure from Baseline to End of Treatment.

​

Male subjects aged 18 to 75 years of age (inclusive) at time of enrollment.

​

​

​

​​

​

Sleep and Microbiome Study

To assess differences in the fecal microbiota and metabolome associated with insufficient and sufficient sleep, and to evaluate the response and recovery of the microbiota to changes in participant sleep profiles.
 

Participants must be men between 20 - 50 years of age or pre-menopausal women between 20 - 45 years of age (inclusive).  Must have a consistent schedule during daytime hours.

​​

​

​

​

 

Natural Short Sleep Study​

A non-interventional study of fecal microbiota in Natural Short Sleepers, individuals who sleep less than average yet wake up feeling refreshed without daytime fatigue.
 

Participants must be men between 20 - 50 years of age or pre-menopausal women between 20 - 45 years of age (inclusive).  Must have a consistent schedule during daytime hours.​

​

​​

​​

 

Bladder Cancer

A Phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Subjects with Intermediate Risk (IR) Non-Muscle Invasive Bladder Cancer (NMIBC).

The subjects must have undergone adequate Transurethral Resection of Bladder Tumor (TURBT) during screening with or without peri-operative intravesical chemotherapy within 60 days prior randomization, and must have one of the following, confirmed by a diagnostic pathology report:

• Recurrence within 1 year, low-grade Ta

• Solitary low-grade Ta >3 cm

• Low-grade Ta, multifocal

• High-grade Ta, ≤3 cm

• Low-grade T1

​​

​

​

​​

​​​​​​​​To see if you qualify for one of the above trials, please send us an email.